View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Fagron completes share buy-back program

Fagron completes share buy-back program Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET Fagron completes share buy-back program In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44,000 of its owns shares at an average price of €20.7208 per share corresponding to a total amount of €911,717.00. A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of € 4,136,093.00. The share buy-back program was announced on ...

 PRESS RELEASE

Voortgang aandeleninkoopprogramma Fagron

Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 14 november 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 10 november 2025 tot en met 14 november 2025 heeft Fagron 44.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20,7208 per aandeel wat overeenkomt met een totaalbedrag van € 911.717,00. Het totaal van 200.000 Fagron aandelen is aangekocht tegen een gemiddelde koers van € 20,6805 per aandeel, wat overeenkomt met een totaalbedrag van € 4.136.093,00. Het aandeleninkoopprogramma was aan...

Mathijs Geerts Danau
  • Mathijs Geerts Danau

Hyloris Positive results for IV Aspirin, NDA will be submitted

Hyloris announced positive topline results from a pivotal study in healthy volunteers for IV aspirin. The trial achieved all its targets, enabling progression towards submission of a New Drug Application (NDA) in 2026 and expected approval in 2027. IV Aspirin is intended to be used in acute coronary syndrome and is part of Hyloris's CV portfolio, for which Hyloris needs to announce a commercial partner in the US. We model € 52m peak sales by 2037. We reiterate our HOLD and € 6 TP.

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Mathijs Geerts Danau
  • Wim Lewi
Marc Zwartsenburg ... (+2)
  • Marc Zwartsenburg
  • CEFA

bpost/A turnaround is not a next day delivery/HOLD

HOLD maintained; target price increased from €1.75 to €1.95 to reflect progress made in the last two quarters and the increase in outlook. However, we also believe tough trading conditions, optimisation of Staci and transformation of Radial US will mean that a recovery of fundamentals cannot be expected in the next quarter(s) as visibility is low and transformation takes time. We do see the longer-term potential but first want to see tangible evidence of margin recovery which validates plugging ...

 PRESS RELEASE

Fagron’s share buy-back program: Weekly update

Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025. The total numbe...

 PRESS RELEASE

Voortgang aandeleninkoopprogramma Fagron

Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 7 november 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 3 november 2025 tot en met 7 november 2025 heeft Fagron 45.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20.4413 per aandeel wat overeenkomt met een totaalbedrag van € 919.856,70. Deze aankopen zijn gedaan als onderdeel van het aandeleninkoopprogramma van maximaal 200.000 Fagron aandelen ter afdekking van Fagron’s verplichtingen uit hoofde van haar langetermijn variabele belonings...

Jacob Mekhael
  • Jacob Mekhael

Galapagos 9M25 conference call feedback

Galapagos reported 9M25 results and hosted a conference call to discuss its results. We provide the key takeaways from the call in this note.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Adecco: 3Q25 strong beat; outlook 4Q25 seems in line. Air France-KLM: Bit light but outlook unchanged. ArcelorMittal: In line 3Q25, supportive medium-term outlook. AMG: 3Q25 EBITDA beats by 5%, ‘only' modest FY guidance increase might disappoint. BAM Group: Maintains outlook as expected. CTP: Guidance at the lower end due to a missed deal in Romania. Strong operational trends continued. IMCD: 3Q showed pressure on gross margin. Kinepolis: US peer AMC; better revenues and EBITDA in ...

Martial Descoutures
  • Martial Descoutures
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Lynn Hautekeete
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : AED BB, COFB BB, GLPG NA, JEN BB, SOLB BB, VGP BB, SHU...

: AED BB, COFB BB, GLPG NA, JEN BB, SOLB BB, VGP BB, SHUR BB, CTPNV NA, IMCD NA, SYENS BB

Stefano Toffano
  • Stefano Toffano
Martial Descoutures
  • Martial Descoutures
Jacob Mekhael
  • Jacob Mekhael

Galapagos 9M25 results hold no surprises, new outlook following cell T...

Galapagos reported 9M25 results with a cash position of € 3,050m (YE24: € 3,317.8m) and an updated outlook, where it expects to end FY25 with € 2,975- € 3,025m in cash, and to incur costs of € 250-325m related to the winddown of the cell therapy business. Looking ahead, the company will focus its strategy on building a new pipeline through BD, and more information on BD strategy will be provided during this afternoon's conference call. € 37 TP and ACCUMULATE maintained.

 PRESS RELEASE

IMCD reports EBITA of EUR 394 million in the first nine months of 2025

IMCD reports EBITA of EUR 394 million in the first nine months of 2025 Rotterdam, The Netherlands (6 November 2025) - IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, today announces its first nine months 2025 results. HIGHLIGHTS Gross profit up by 2% to EUR 927 million (+5% on a constant currency basis)Operating EBITA down by 2% to EUR 394 million (+1% on a constant currency basis)Free cash flow of EUR 284 million (first nine months 2024: EUR 299 million)Cash earnings per share at EUR 4.16 (first nine ...

 PRESS RELEASE

Galapagos Reports Nine Months 2025 Financial Results and Provides Busi...

Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a  tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch